-
公开(公告)号：US5639651A
公开(公告)日：1997-06-17
申请号：US287959
申请日：1994-08-09
CPC分类号： C07K14/4706 , C07K14/82 , A61K38/00 , A61K48/00 , C07K2319/00
摘要： A purified nucleic acid encoding the IQGAP1 protein, a novel member of the GTPase activating protein family, useful in the diagnosis and treatment of tumors.
摘要翻译： 编码IQGAP1蛋白的纯化核酸，其是GTP酶活化蛋白家族的新成员，可用于诊断和治疗肿瘤。
-
公开(公告)号：US20080096212A1
公开(公告)日：2008-04-24
申请号：US11894135
申请日：2007-08-20
申请人： Daphne Bell , Daniel Haber , Pasi Janne , Bruce Johnson , Thomas Lynch , Matthew Meyerson , Juan Paez , William Sellers , Jeffrey Settleman , Raffaella Sordella
发明人： Daphne Bell , Daniel Haber , Pasi Janne , Bruce Johnson , Thomas Lynch , Matthew Meyerson , Juan Paez , William Sellers , Jeffrey Settleman , Raffaella Sordella
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/485 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/574 , G01N33/74 , G01N2333/485 , G01N2800/52
摘要： The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
-
公开(公告)号：US20060147959A1
公开(公告)日：2006-07-06
申请号：US11294621
申请日：2005-12-05
申请人： Daphne Bell , Daniel Haber , Pasi Janne , Bruce Johnson , Thomas Lynch , Matthew Meyerson , Juan Paez , William Sellers , Jeffrey Settleman , Raffaella Sordella
发明人： Daphne Bell , Daniel Haber , Pasi Janne , Bruce Johnson , Thomas Lynch , Matthew Meyerson , Juan Paez , William Sellers , Jeffrey Settleman , Raffaella Sordella
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/485 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/574 , G01N33/74 , G01N2333/485 , G01N2800/52
摘要： The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
-
-
搜索结果
3 条记录 (耗时 0.019 秒)
